Shots:  

• Q1’2025 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The talk of the town remained Intra-Cellular Therapies’ acquisition by Johnson & Johnson for ~$14.6B  

• The quarter highlighted breakthrough results, pivotal clinical data, including Eli Lilly and Incyte's P-III Study Data of Baricitinib to treat Alopecia Areata 

• PharmaShots brings the Quarterly digest compiling insights from Jan’25 to Mar’25 

 

Galera Therapeutics Completes Nova Pharmaceuticals’ Acquisition 

Date: Jan 1, 2025 

Product: NA 

Shots: 

• Galera has completed Nova’s acquisition to form Galera Therapeutics, trading on OTC under GRTX ticker. Acquisition was backed by a $3M investment from a group of investors led by Ikarian Capital 

• Galera issued 21.1M common shares, pre-funded warrants for 23M shares & 119,318 Series B convertible preferred shares. At closing, Galera stockholders will own ~55.2% of shares (assuming full warrant exercise) & post preferred stock conversion approval, they will own 25%, with new investors & Nova stockholders owning 75% of the combined entity 

• The entity will advance P-I/II study of pan-NOS inhibitor + nab-paclitaxel & alpelisib in MpBC, with another trial exploring it in TNBC. A P-III trial of avasopasem for HR+ ABC resistant to conventional therapy is planned in H1’25 

  

Stryker to Acquire Inari Medical for ~$4.9B 

Date: Jan 1, 2025 

Product: NA 

Shots: 

• Stryker has signed a definitive agreement to initiate a tender offer for acquiring all the issued & outstanding shares of Inari Medical for $80 per share in cash, making it a total value of ~$4.9B 

• Upon completion, Stryker will acquire remaining shares in a second-step merger at the same price. The deal is expected to close by Q1’25, pending customary conditions 

• The acquisition adds Inari's mechanical thrombectomy solutions for deep vein thrombosis & pulmonary embolism to Stryker’s neurovascular business, bolstering its position in the peripheral vascular segment, mainly in venous thromboembolism (VTE) 

  

Hologic Completes the Acquisition of Gynesonics for ~$350M 

Date: Jan 7, 2025 

Product: Sonata System 

Shots: 

• Hologic has completed the acquisition of Gynesonics, focused on developing minimally invasive women’s health solutions, for ~$350M 

• The acquisition has strengthened Hologic's portfolio with the addition of Sonata System, a minimally invasive solution for heavy periods & fibroids 

• The Sonata System is developed to capture intrauterine images for diagnosis and transcervical treatment of symptomatic uterine fibroids, incl. those with heavy menstrual bleeding. It uses real-time ultrasound guidance & radiofrequency ablation for an incisionless procedure 

 

Boston Scientific to Acquire Bolt Medical, Strengthening its Cardiovascular Portfolio 

Date: Jan 9, 2025 

Product: Bolt IVL System  

Shots: 

• Boston Scientific has agreed to acquire Bolt Medical, strengthening its cardiovascular portfolio with the addition of Bolt IVL system for coronary & peripheral disease. Deal is expected to close in H1’25 

• Boston, an investor with a 26% equity stake in Bolt Medical, is acquiring the rest 74% for $443M upfront & up to $221M regulatory milestones. (Deal is valued at $600M upfront & up to $300M milestones if the acquisition was for 100% stake) 

• The Bolt IVL System uses lithotripsy to remove calcium in calcified lesions. The pivotal (RESTORE ATK & BTK) studies of Bolt IVL ATK & BTK Systems for PAD are completed, with data supporting the FDA’s approval & CE mark; another global FRACTURE IDE trial of Bolt IVL Coronary System for CAD has begun in Dec 2024 

 

Transcarent to Acquire Accolade for ~$621M 

Date: Jan 9, 2025 

Product: NA 

Shots: 

• Transcarent to acquire Accolade with a total equity value of ~$621M, with shareholders receiving $7.03/share in cash, making Accolade private. Closing expected in Q2’25 

• The acquisition will yield a unified platform with Transcarent’s WayFinding (generative AI), pharmacy benefits & overall care experiences (incl. weight health, cancer & surgery care) & Accolade’s data of advocacy, EMO, & primary care 

• The platform will offer custom & superior services at lower cost, plus a broad local database for its members while reducing physician workload by easier access & less paperwork, leveraging the benefits of both company's platforms   

 

GSK to Acquire IDRx for ~1.15B, Boosting its GI Cancer Portfolio 

Date: Jan 13, 2025 

Product: IDRX-42 

Shots: 

• GSK to acquire IDRx incl. its lead candidate IDRX-42, for $1B upfront & ~$150M in regulatory milestones (total ~$1.15B). It will also pay success-based milestones & tiered royalties to Merck KGaA for IDRX-42 

• IDRX-42 (TKI, small molecule) targets key KIT mutations, responsible for proliferation & survival of tumor cells, & is under P-I/Ib (StrateGIST 1) trial for 1L & 2L treatment of greater GIST & KIT mutated patients. GSK will expedite the development this year 

• The study showed ORR of 29% (n=87, incl. 1 CR & 24 PRs) in efficacy-evaluable 2L patients & 53% (n=15, incl. 1 CR & 7PRs) in those who received 1L therapy; 2 PRs were awaiting verification at the cut off. Safety was favorable, with data highlighted at CTOS 2024 

 

Johnson & Johnson to Acquire Intra-Cellular Therapies for ~14.6B, Boosting its Neuroscience Portfolio 

Date: Jan 14, 2025 

Product: Caplyta & ITI-1284 

Shots: 

• J&J entered into a definitive agreement to acquire Intra-Cellular Therapies, incl. its drugs Caplyta & ITI-1284, for a total equity value of ~14.6B (cash + debt), with shareholders receiving $132/share in cash, making the latter private 

• In Dec 2024, the latter filed an sNDA to the US FDA for Caplyta as adj. therapy for MDD. In addition, 2 P-III trials showed improved depressive symptoms & favorable safety, with additional P-III trials for bipolar I mania underway 

• Caplyta (oral, QD) modulates serotonin (5-HT2A) & Dopamine (D2) receptors to treat schizophrenia & bipolar depression while ITI-1284 is in P-II trials for the treatment of GAD & AD related psychosis & agitation 

 

Eli Lilly Inks ~2.5B Deal to Acquire Scorpion Therapeutics 

Date: Jan 14, 2025 

Product: STX-478 

Shots: 

• Eli Lilly to acquire Scorpion, plus its leading asset STX-478, for ~2.5B in cash, incl. upfront, regulatory & sales milestones through a definitive agreement 

• As per the terms, Scorpion will form an independent company owned by its current shareholders with Lilly’s minority stake to hold its employees & non-PI3Kα pipeline assets 

• STX-478 (oral, QD) inhibits mutated PI3Kα forms & is currently subjected to P-I/II studies for the treatment of HR+ve breast cancer & other advanced solid tumors 

 

Lantheus Holdings to Acquire Evergreen Theragnostics for ~$1B 

Date: Jan 29, 2025 

Product: Octevy 

Shots: 

• Lantheus will acquire Evergreen Theragnostics for $250M upfront plus ~$752.5M development & sales milestones related to Octevy & other assets in an all-cash transaction, with closing anticipated in H2’25 pending regulatory approvals 

• The acquisition will add Evergreen’s Octevy (registrational-stage PET imaging agent for somatostatin receptor +ve NETs in adults & pediatrics) complementing Lantheus' PNT2003, a drug discovery & early-stage clinical development tech as well as early-stage oncology & radiotherapeutic candidates 

• Lantheus will also acquire Evergreen’s RLT manufacturing infrastructure, revenue-generating CDMO business as well as isotope expertise, enhancing development, production & long-term growth 

  

Zimmer Biomet to Acquire Paragon 28 for ~$1.2B 

Date: Jan 29, 2025 

Product: N/A 

Shots:  

• Zimmer Biomet has agreed to acquire Paragon 28 for $13.00/share in cash with an equity value of ~$1.1B & enterprise value of ~$1.2B. Closing is expected in H1’25 

• As per the terms, shareholders will also get a non-tradeable CVR of $1/share on achieving revenue milestones, which is payable from $0 to $1 (calculated linearly) if Zimmer’s FY’26 net sales exceed $346M up to $361M 

• The acquisition will strengthen Zimmer’s portfolio with Paragon 28’s leading platform technology along with pipeline in foot & ankle surgical solutions incl. deformity correction, joint replacement, fracture & trauma 

  

Alumis Signs a Definitive Merger Agreement with ACELYRIN to Develop Novel Therapies for Immune-mediated Diseases 

Date: Feb 7, 2025 

Product: ESK-001, A-005 & Lonigutamab 

Shots: 

• Alumis & ACELYRIN have entered into a definitive agreement to merge, with ACELYRIN stockholders receiving 0.4274 Alumis shares/share, owning 45% of the combined entity - "Alumis"; closing expected in Q2’25 

• As of Dec 31, 2024, Alumis & ACELYRIN had ~$289M & ~$448M in cash as well as investments, respectively, with a pro forma total of ~$737M to fund clinical trials & operations into 2027 

• Merged pipeline incl. Alumis’ ESK-001 (P-III ONWARD topline data for PsO in H1’26, P-IIb LUMUS topline data for SLE in 2026, & 52wk. P-II OLE update in 2025) & A-005 (P-II trial in MS starting H2’25 with topline data in 2026), plus ACELYRIN’s lonigutamab (P-II trial showing robust efficacy in TED; development plan is under evaluation) 

  

Bain Capital to Acquire Mitsubishi Tanabe Pharma for ~$3.3B 

Date: Feb 7, 2025 

Product: N/A 

Shots: 

• Bain Capital has signed to acquire Mitsubishi Tanabe Pharma in a carve-out deal from Mitsubishi Chemical Group at ~510 billion JPY (3.3 billion USD), is led by Bain Capital’s Private Equity teams in Asia, North America, and its Life Sciences team. 

• The transaction is expected to close in Q3’25, pending regulatory approval, shareholder approvals, and customary closing conditions. 

• Bain Capital's global Healthcare platform has multiple companies such as Avistone Pharma, Cardurion Pharma, Kailera Therapeutics, Stada and more and few which are now acquired such as Aiolos Bio (now GSK), Cereval Therapeutics (now AbbVie) 

  

Novartis to Acquire Anthos Therapeutics for ~$3.1B 

Date: Feb 11, 2025 

Product: Abelacimab 

Shots: 

• Novartis to acquire Anthos (launched by Blackstone Life Sciences & Novartis in 2019) for ~$3.1B to boosts its cardiovascular portfolio with Anthos’ abelacimab; closing expected in H1’25 

• As per the deal, Anthos will receive $925M upfront & is eligible to receive ~$2.15B in regulatory & commercial milestones 

• Abelacimab (licensed from Novartis) showed reduced bleeding events in P-II (AZALEA) trial in comparison to SoC oral anticoagulants & is being investigated in 3 ongoing P-III (LILAC-TIMI 76 for atrial fibrillation; ASTER & MAGNOLIA for cancer-associated thrombosis) trials to prevent stroke & systemic embolism 

  

Regeneron and Sanofi Report the US FDA’s sBLA Acceptance for Dupixent to Treat Bullous Pemphigoid (BP) 

Date: Feb 18, 2025 

Product: Dupixent 

Shots: 

• The US FDA has accepted & granted priority review to the sBLA of Dupixent for the treatment of adults with BP (PDUFA: Jun 20, 2025) 

• sBLA was supported by P-II/III (ADEPT) trial assessing Dupixent vs PBO in pts (n=106) for 52wks., that met its 1EP of 5x pts achieving sustained disease remission at 36wks. (full clinical remission, OCS-free by 16wks., on Dupixent ≥20wks. with no relapse or rescue therapy use). Reduced disease severity, itch & OCS use was also observed 

• Additionally, Dupixent (anti-IL-4/IL-13 mAb) is being investigated in various P-III trials for multiple inflammatory diseases incl. chronic pruritus of unknown origin, BP, & lichen simplex chronicus 

  

The US FDA Accepts NDA of Boehringer Ingelheim’s Zongertinib for HER2 (ERBB2)-Mutant NSCLC 

Date: Feb 20, 2025 

Product: Zongertinib 

Shots: 

• The US FDA has accepted & granted priority review to the NDA of zongertinib (BI 1810631) for the treatment of pts with inoperable or metastatic NSCLC harboring HER2 (ERBB2) mutations who have received prior systemic therapy (PDUFA: Q3’25) 

• Submission was based on P-Ib (Beamion LUNG-1) trial assessing zongertinib as Monotx. in 2 arms (Arm 1: solid tumors with HER2 alterations, unresponsive to previous therapy & Arm 2: NSCLC with specific HER2 mutation) that showed improved ORR of 71%, with 6mos. PFS of 69% & DoR rate of 73% in Arm 1 (n=75) 

• Zongertinib is being evaluated in an ongoing P-III (Beamion LUNG-2) trial assessing it vs SoC in above mentioned pts 

  

Cosette Pharmaceuticals to Acquire Mayne Pharma for ~$430M 

Date: Feb 21, 2025 

Product: Vyleesi, Intrarosa, Nextstellis, Annovera, Bijuva, Imvexxy, & Rhofade 

Shots: 

• Cosette Pharmaceuticals to acquire Mayne Pharma Group for ~$430M, with shareholders receiving $4.71/share. Closing expected in Q2’25 

• Acquisition will strengthen Cosette’s dermatology & women’s health business, adding 12 patent-protected products incl. Vyleesi, Intrarosa, Nextstellis, Annovera, Bijuva, Imvexxy, & Rhofade along with multiple pipeline candidates in its product line upon closing 

• The combined entity will have 2 state of the art, FDA-approved manufacturing sites in Lincolnton, North Carolina, & Salisbury, South Australia, enhancing access to women's health therapies globally 

 

 AstraZeneca Purchases FibroGen China for ~$160M 

Date: Feb 21, 2025 

Product: Roxadustat 

Shots: 

• AstraZeneca has purchased FibroGen’s China subsidiary for ~$160M ($85M enterprise value + ~$75M net cash) with closing expected in mid-2025, obtaining full rights to roxadustat in China 

• The sale allows FibroGen to repay its Morgan Stanley Tactical Value loan & extend its cash runway to 2027 for advancing FG-3246 in P-II trial for mCRPC (expected to begin in Q2’25) & develop its companion PET imaging agent, FG-3180 

• Additionally, FibroGen retains rights to roxadustat in the US & non-Astellas markets & plans to develop roxadustat in anemia with LR-MDS. FDA meeting is planned in Q2’25 for roxadustat development program in US 

  

Carlyle & SK Capital to Acquire Bluebird Bio 

Date: Feb 24, 2025 

Product: N/A 

Shots:   

• Carlyle & SK Capital have entered into definitive agreement to acquire Bluebird Bio for $3/share in cash, delisting it from public market. Acquisition will fund Bluebird’s commercial delivery of gene therapies for SCD, β-thalassemia, & cerebral adrenoleukodystrophy, with closing expected in H1’25 

• As per the deal, Bluebird stockholders will get $3/share & contingent value right (CVR)/share allowing stockholders to receive additional $6.84/CVR in cash if Bluebird achieves $600M in net sales within 12mos. trailing period ending on Dec 31, 2027 

• Bluebird has also amended loan terms with Hercules Capital to secure liquidity for sustaining operations until closing 

  

Thermo Fisher Scientific to Acquire Solventum’s Purification & Filtration Business for ~$4.1B 

Date: Feb 26, 2025 

Product: N/A 

Shots: 

• Thermo Fisher has entered into definitive agreement with Solventum to acquire its purification & filtration business for ~$4.1B in cash, adding value to its upstream and downstream biologics development & manufacturing  

• Transaction is expected to close by the end of 2025, pending regulatory approval & customary closing conditions 

• Solventum's purification and filtration unit has team of 2,500 spread globally and generated ~$1B in 2024. Solventum's P&F is complimentary to Thermofisher's cell culture media and single use technologies for biologics development 

  

Teleflex Enters a Definitive Agreement to Acquire BIOTRONIK’s Vascular Intervention Business for ~$797.7M (€760M) 

Date: Feb 28, 2025 

Product: Pantera Lux Catheter, PK Papyrus Covered Stent, Orsiro Stent, Passeo-18 Lux Catheter, Dynetic-35 Stent, & Pulsar-18 T3 4F Stent 

Shots: 

• Teleflex to acquire BIOTRONIK's vascular intervention business for ~$797.7M (€760M) in cash, subject to adjustments. Closing expecting in Q3’25 

• Acquisition will expand Teleflex’s interventional portfolio with coronary products like Pantera Lux Catheter, PK Papyrus Covered Stent & Orsiro Stent, plus peripheral product like Passeo-18 Lux Catheter, Dynetic-35 Stent, & Pulsar-18 T3 4F Stent, complementing to its PCI platform 

• Acquisition also allows Teleflex to advance development of BIOTRONIK’s Freesolve, which was assessed in the BIOMAG-I trial showing superior post 12mos. resorbability & target lesion failure rate with no scaffold thrombosis. Enrolment is ongoing in European BIOMAG-II trial 

 

BridgeBio Oncology Therapeutics (BBOT) Enters into Business Combination Agreement with Helix Acquisition Corp. II to Develop RAS and PI3Kα-Targeting Drugs 

Date: Mar 3, 2025 

Product: BBO-8520 

Shots: 

• BBOT will reverse merge with Helix in a SPAC transaction, where combined entity - "BBOT” will be listed on Nasdaq; closing expected in Q3’25 

• Upon closing, BBOT will have ~$550M cash (pre-transaction) incl. $100M in existing cash, $196M from Helix’s trust & $260M from PIPE financing. At $10.36/share, the combined entity's implied pro forma equity value is ~$949M, with BBOT shareholders rolling 100% of their equity 

• Combined entity will develop BBO-8520 in the P-I (ONKORAS-101) trial for KRAS^G12C mutant NSCLC, BBO-10203 in the P-I (BREAKER-101) trial for HER2+ & HR+/HER2- breast cancer, KRAS mCRC, & KRAS mutant NSCLC, as well as BBO-11818, with first pts dosing in H1’25 

  

Boston Scientific Enters into a Definitive Agreement to Acquire SoniVie for $600M 

Date: Mar 4, 2025 

Product: TIVUS Intravascular Ultrasound System  

Shots: 

• Boston Scientific entered into a definitive agreement to acquire SoniVie Ltd. to expand its  interventional cardiology therapies offerings 

• Currently, the company holds an equity stake of approx. 10%, and for the remaining 90% stake, the company will pay approx. $360M upfront and up to $180M regulatory milestones; for 100% stake, the amount sums up to $400M upfront and $200M regulatory milestone; transaction completion is expected in H1’25 

• TIVUS Intravascular Ultrasound System is the lead asset of the company that is an investigational device developed to treat a variety of hypertensive disorders, incl. renal artery denervation, and currently the device is being investigated in THRIVE global IDE pivotal trial  

 

KYORIN and Novartis Sign a $832.5M Global License Agreement for KRP-M223 

Date: Mar 4, 2025 

Product: KRP-M223 

Shots: 

• KYORIN and Novartis entered into a global license agreement for KRP-M223 and its back-up compounds discovered by KYORIN 

• As per the agreement, Novartis gets an exclusive global license to develop, manufacture, and commercialize KRP-M223, where KYORIN retains an option to commercialize and manufacture product for the Japanese market, with Novartis retaining an option to co-promote with KYORIN in Japan. Additionally, KRP-M223 is in pre-clinical stage, and Novartis will handle its global development 

• KYORIN will receive $55M upfront payment and up to $777.5M milestone payments based on the progress of development, approval, and commercialization of KRPM223, along with tiered royalties on net sales 

   

Jazz Pharmaceuticals to Acquire Chimerix for ~$935M 

Date: Mar 6, 2025 

Product: Dordaviprone 

Shots: 

• Jazz Pharmaceuticals to acquire Chimerix for ~$935M at a price of $8.55 per share in cash. Upon completion in Q2’25, Jazz will acquire remaining shares via second-step merger 

• Acquisition will strengthen Jazz’s rare oncology presence through development & launch of Chimerix’s lead asset, dordaviprone, while adding durable revenue potential with patent protection through 2037 & possible extension 

• Dordaviprone is under the US FDA priority review (PDUFA: Aug 18, 2025) with potential RPD PRV post approval, plus it is being evaluated in an ongoing P-III (ACTION) trial for naïve, non-recurrent H3 K27M-mutant glioma post-radiation, potentially expanding its use to 1L pts  

  

Sun Pharma to Acquire Checkpoint Therapeutics For ~$355M 

Date: Mar 10, 2025 

Product: Unloxcyt 

Shots: 

• Sun Pharma to acquire Checkpoint Therapeutics for ~$355M to strengthen its onco-derm innovative portfolio with Unloxcyt (cosibelimab-ipdl); closing expected in Q2’25   

• As per the deal, Checkpoint stockholders will get $4.10 cash/share (~66% premium) upfront & CVR/share without interest allowing stockholders to receive additional $0.70 cash/share if Unloxcyt is approved before certain deadlines in the EU or in Germany, France, Italy, Spain or UK as per CVR agreement 

• Checkpoint, Sun, & Fortress Biotech have also signed royalty agreement, granting Fortress royalties on future Unloxcyt sales during a specified term, replacing prior rights from Checkpoint’s establishment after closing 

 

Eli Lilly and Incyte Highlight P-III (BRAVE-AA-PEDS) Trial Data of Baricitinib for Alopecia Areata at AAD 2025 

Date: Mar 11, 2025 

Product: Baricitinib 

Shots: 

• The P-III (BRAVE-AA-PEDS) trial assessed baricitinib (2 or 4mg, QD, PO) vs PBO in 257 pts (12 to <18yrs.) with severe AA, where 89% had significant scalp hair loss, 65% had minimal/no eyebrow hair, & 57% had minimal/no eyelash hair with ClinRO of 2/3; next cohort (6 to <12yrs) enrollment to start in 2026    

• Trial at 36wks. showed 60% (4mg) & 36.9% (2mg) pts had ~50% SALT improvement vs 5.7%; 42.4% (4mg) & 27.4% (2mg) pts achieved ≥80% scalp coverage (1EP) vs 4.5%, while 36.5% (4mg) & 21.4% (2mg) had ≥90% coverage (SALT ≤10) vs 2.3% 

• 50% (4mg) & 24.1% (2mg) pts on baricitinib had significant eyebrow regrowth vs 0%. For eyelash regrowth, 42.9% (4mg) & 25.5% (2mg) showed improvement vs 14%  

  

AstraZeneca to acquire EsoBiotec for ~$1B 

Date: Mar 18, 2025 

Product: N/A 

Shots: 

• AstraZeneca to acquire EsoBiotec, which will operate as AstraZeneca’s subsidiary, while maintaining its operations in Belgium to advance cell therapy 

• As per the deal, AstraZeneca will acquire all outstanding equity of EsoBiotec on a cash & debt-free basis for ~$1B, incl. $425M upfront at closing & ~$575M in development & regulatory milestones; closing is expected Q2’25 

• Acquisition will add EsoBiotec’s ENaBL platform, enhancing AstraZeneca’s cell therapy capabilities by utilizing targeted lentiviruses which can be administered via IV to deliver genetic instructions to immune cells, programming them to destroy tumor cells without immune cell depletion 

  

Endo & Mallinckrodt Pharmaceuticals to Form a Combine Entity with $6.7B Cash-and-Stock 

Date: Mar 18, 2025 

Product: N/A 

Shots: 

• Mallinckrodt & Endo to combine their generic pharmaceuticals & Endo’s sterile injectables businesses, later separating the unit, with combined company headquartered in Dublin, Ireland & Endo operating as Mallinckrodt’s subsidiary    

• As per the deal, Endo shareholders will receive $80M in cash & own 49.9% of the combined company, while Mallinckrodt shareholders will hold 50.1%, with a $6.7B implied pro forma enterprise value. Combined entity will be listed on NYSE following closing in H2’25 

• Merged product portfolio will comprise branded generics incl. Xiaflex, Acthar Gel, Terlivaz, Supprelin LA & Aveed, plus the combined entity will operate 17 manufacturing sites, 30 distribution centers & ~5,700 employees at closing 

  

Taiho Pharmaceutical to Acquire Araris Biotech for ~$1.1B 

Date: Mar 19, 2025 

Product: N/A 

Shots: 

• Taiho Pharmaceutical has entered into a definitive agreement to acquire Araris Biotech following a 2023 research collaboration between them; closing expected in H1'25 

• As per the deal, Araris Biotech will receive $400M upfront at closing & ~$740M in milestones, becoming a wholly owned subsidiary of Taiho Pharmaceutical, while continuing its operations in Zurich, Switzerland 

• Acquisition will strengthen Taiho’s ADC portfolio with Araris’s AraLinQ platform & 3 preclinical assets set for clinical development in 2025-2026. Taiho also aims to advance its oncology pipeline by integrating its Cysteinomix drug discovery platform with the AraLinQ 

  

Paratek Pharmaceuticals to Acquire Optinose for ~$330M, Expanding its Commercial Portfolio 

Date: Mar 21, 2025 

Product: Xhance 

Shots: 

• Paratek has entered into a definitive merger agreement to acquire Optinose incl. its approved product, Xhance for ~330M, delisting it from NASDAQ; closing expected by mid-2025 

• As per the deal, Optinose stockholders will receive $9/share in cash (50% premium as per Mar 19, 2025) & CVR of $5/share on achieving revenue milestones, where they will get $1/share if Xhance reaches $150M in net sales & $4/share if it reaches $225M before Dec 31, 2029 

• XHANCE (fluticasone propionate) uses a proprietary exhalation delivery system (EDS) to precisely target inflammation sites for treating CRS, with or without nasal polyps 

  

Related Post: PharmaShots' Key Highlights of Fourth Quarter 2024